Tempus AI, Inc. (NASDAQ:TEM) Director Sells $136,620.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Wayne A.I. Frederick sold 3,000 shares of the business’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the transaction, the director now owns 26,514 shares in the company, valued at $1,207,447.56. This represents a 10.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Stock Performance

TEM stock opened at $46.17 on Friday. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The firm has a fifty day moving average price of $58.45 and a two-hundred day moving average price of $51.51. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TEM. GF Fund Management CO. LTD. acquired a new stake in Tempus AI during the fourth quarter worth about $108,000. Voloridge Investment Management LLC bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $11,826,000. Two Sigma Advisers LP bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $625,000. ProShare Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $244,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $1,034,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on TEM. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Bank of America upped their target price on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Piper Sandler reduced their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.